Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

15th Milan Breast Cancer Conference /
Advances in treatment of triple negative breast cancer

20th - 21st Jun 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.07.13
Views: 5150
Rating:

Dr Clifford Hudis - Memorial Sloan-Kettering Cancer Center, New York, USA

Dr Clifford Hudis talks to ecancer at MBCC 15 about triple negative breast cancer and the need to develop subtypes for this specific type of breast cancer in order to develop new targeted therapies.

This is already being done with gene expression profiling and an example where it has been successful is with androgen receptors and treating with the prostate cancer drug bicalutamide.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation